Industry News
According to Reuters and other foreign media reports, Angela Lukin, a Pfizer executive, recently publicly said that after the expiration of the U.S. government's procurement plan, the price of COVID-19 vaccine will be significantly increased, with each dose selling at $110 to $130, about four times the current government procurement price.
The trade name of Pfizer COVID-19 vaccine in the United States is Comirnaty, which is an mRNA vaccine developed based on the proprietary mRNA technology platform of its partner BioNTech, a German biotechnology company. COVID-19 vaccine was approved and launched in the United States at the end of 2020 at the earliest. At present, the vaccine is free of charge in the United States, and the government bears the related costs. The price of each dose of COVID-19 vaccine is 30.5 dollars.
ABC reported that, according to the data of the Centers for Disease Control and Prevention (CDC), more than 375 million doses of Pfizer COVID-19 vaccine have been distributed in the United States. It can be seen that Pfizer has not stopped on the COVID-19 vaccine. On the one hand, it is to expand the vaccination age of COVID-19 vaccine, and on the other hand, it is to promote the research and development of the upgraded version of COVID-19 vaccine. On October 12, local time, Pfizer announced that the United States provided the upgraded Pfizer vaccine to the group aged 5 to 11 as an enhancement dose through emergency use authorization.
Pfizer believes that the market size of COVID-19 vaccine is expected to reach the size of adult influenza vaccine, but according to the current vaccination situation, it will take longer to establish the children's market.
Or affected by the above news, as of October 21, the U.S. stock market closed, Pfizer rose 4.83% to close at 44.95 dollars per share
报错
笔记